Zevra Therapeutics, Inc. (ZVRA) Financials

ZVRA Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 278.6 million 72.8 million
Dec. 31, 2025 284.7 million 130.1 million
Sept. 30, 2025 270.1 million 137.0 million
June 30, 2025 256.3 million 139.0 million

ZVRA Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 6.1 million 3.1 million
Dec. 31, 2025 5.5 million 4.3 million
Sept. 30, 2025 4.2 million 2.8 million
June 30, 2025 -3.8 million 2.5 million

ZVRA Net Income

No data available :(

ZVRA Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 95.6 million 741000 -
Dec. 31, 2025 191.0 million 61.9 million 859000
Sept. 30, 2025 199.5 million 61.3 million 966000
June 30, 2025 202.6 million 60.7 million 1.6 million

ZVRA Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 60.2 million
Dec. 31, 2025 57.3 million
Sept. 30, 2025 56.0 million
June 30, 2025 56.3 million

ZVRA Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 35000 4.4 million 20.8 million -
Dec. 31, 2025 31000 2.6 million 20.4 million -
Sept. 30, 2025 554000 3.4 million 16.9 million -
June 30, 2025 213000 3.4 million 20.8 million -

ZVRA Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 36.2 million 2.3 million
Dec. 31, 2025 34.1 million 1.5 million
Sept. 30, 2025 26.1 million 1.6 million
June 30, 2025 25.9 million 12.4 million

ZVRA Revenue by Segment
Graph available only for paid members. Upgrade to see it.

ZVRA

Price: $12.62

52 week price:
7.16
13.66

Earnings Per Share: 2.01 USD

P/E Ratio: 5.37

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Market Capitalization: 647.9 million

Links: